Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309507 | 0.86 | JAK2 (0.49) | JAK2JAK3KDRPLK1FLT1 | |
| SCHEMBL3300957 | 0.85 | JAK2 (0.50) | JAK2JAK3KDRPLK1IKBKB | |
| SCHEMBL3306130 | 0.85 | JAK2 (0.46) | JAK2LRRK2JAK3PLK1IKBKB | |
| SCHEMBL3301223 | 0.85 | KDR (0.52) | JAK2LRRK2JAK3KDRPLK1 | |
| SCHEMBL3300054 | 0.84 | JAK2 (0.46) | JAK2LRRK2JAK3KDRPLK1 | |
| SCHEMBL3304261 | 0.83 | JAK2 (0.48) | JAK2LRRK2JAK3KDRPLK1 | |
| SCHEMBL3304002 | 0.82 | JAK2 (0.45) | JAK2LRRK2JAK3KDRPLK1 | |
| SCHEMBL3309445 | 0.82 | JAK2 (0.46) | JAK2LRRK2JAK3KDRFLT4 | |
| SCHEMBL3306057 | 0.81 | ADORA2A (0.46) | JAK2LRRK2JAK3KDRPLK1 | |
| SCHEMBL3304308 | 0.81 | JAK2 (0.43) | JAK2LRRK2JAK3KDRPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK2 26/4885LRRK2 98/4885JAK3 86/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK2 26/4885LRRK2 98/4885JAK3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.